Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis

Di, Mengyang; Long, Jessica B.; Kothari, Shalin; Sethi, Tarsheen; Zeidan, Amer M.; Podoltsev, Nikolai A.; Shallis, Rory M.; Wang, Rong; Ma, Xiaomei; Huntington, Scott F.

doi:10.3324/haematol.2022.282252

Cited by 3 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A prospective randomized controlled trial found that R maintenance after BR regimen did not improve PFS and OS in patients with MCL 22 . Recently, two real‐world studies of large samples found that R maintenance after BR regimen had a longer time to the next treatment and OS than the observation group 39,40 . Our results showed that BR+R regimen may have better PFS than BR regimen, but OS did not improve.…”

Section: Discussionmentioning

confidence: 49%

“…22 Recently, two real-world studies of large samples found that R maintenance after BR regimen had a longer time to the next treatment and OS than the observation group. 39,40 Our results showed that BR+R regimen may have better PFS than BR regimen, but OS did not improve. A growing body of observational data supports R maintenance after BR therapy in elderly patients with MCL who do not receive autologous stem cell transplantation.…”

Section: Regimenmentioning

confidence: 75%

See 1 more Smart Citation

Efficacy of front‐line immunochemotherapy for transplant‐ineligible mantle cell lymphoma: A network meta‐analysis of randomized controlled trials

et al. 2023

View full text Add to dashboard Cite

BackgroundThere is no standard first‐line immunochemotherapy regimen for transplant‐ineligible patients with mantle cell lymphoma (MCL) currently, and the efficacy of various treatment remains unclear.MethodsWe conducted a Bayesian network meta‐analysis (NMA) of all eligible randomized controlled trials. Pairwise comparisons and ranking of different first‐line treatment options were performed.ResultsNine studies were included in the NMA, involving a total of 2897 MCL patients. The BR‐Ibrutinib+R regimen showed the best progression‐free survival (PFS), with a surface under the cumulative ranking curve (SUCRA) of 0.89 and probability of being the best treatment (PbBT) of 69%. The VR‐CAP regimen was the most potential intervention to improve overall survival (OS), with a SUCRA of 0.89 and PbBT of 63%. Compared with the R‐CHOP regimen, the BR regimen achieved a better PFS (hazard ratio [HR] 0.45 [95% credible interval 0.2–0.96]). The BR‐Ibrutinib+R regimen (HR 0.14 [0.02–0.99]), BR+R regimen (HR 0.19 [0.034–0.99]), and BR regimen (HR 0.3 [0.08–1.03]) were superior to CHOP regimen with better PFS. The R‐FC regimen (HR 2.27 [1.01–5.21]) or FC regimen (HR 3.17 [1.15–8.71]) was inferior to the VR‐CAP regimen with a worse OS.ConclusionsOur study presents the most promising first‐line treatment strategy for transplant‐ineligible MCL patients in terms of PFS and OS, which provides innovative treatment strategy for MCL treatment.

show abstract

Section: Discussionmentioning

confidence: 49%

Section: Regimenmentioning

confidence: 75%

Efficacy of front‐line immunochemotherapy for transplant‐ineligible mantle cell lymphoma: A network meta‐analysis of randomized controlled trials

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The main limitation of our study is represented by the retrospective nature of the study and the reduced sample size, and this may explain why some classic prognostic factors, such as MIPI score and stage, did not affect PFS and OS in our cohort. Another limitation is that patients did not receive rituximab as maintenance therapy, which may ensure further PFS and OS improvement in future studies [ 10 , 47 ].…”

Section: Discussionmentioning

confidence: 99%

Survival Outcomes of Patients with Mantle Cell Lymphoma: A Retrospective, 15-Year, Real-Life Study

Cencini,

Calomino,

Franceschini

et al. 2024

Hematology Reports

View full text Add to dashboard Cite

Mantle cell lymphoma (MCL) prognosis has significantly improved in recent years; however, the possible survival benefit of new treatment options should be evaluated outside of clinical trials. We investigated 73 consecutive MCL patients managed from 2006 to 2020. For younger patients <65 years old, the median PFS was 72 months and we reported a 2-year, 5-year, and 10-year PFS of 73%, 62%, and 41%; median OS was not reached and we reported a 2-year, 5-year, and 10-year OS of 88%, 82%, and 66%. For patients aged 75 years or older, the median PFS was 36 months and we reported a 2-year, 5-year, and 10-year PFS of 52%, 37%, and 37%; median OS was not reached and we reported a 2-year, 5-year, and 10-year OS of 72%, 55%, and 55%. The median PFS was significantly reduced for patients treated between 2006 and 2010 compared to patients treated between 2011 and 2015 (p = 0.04). Interestingly, there was a trend towards improved OS for patients treated between 2016 and 2020 compared to between 2006 and 2010 and between 2011 and 2015 (5-year OS was 91%, 44%, and 33%). These findings could be due to the introduction of BR as a first-line regimen for elderly patients and to the introduction of ibrutinib as a second-line regimen.

show abstract

Challenges of treating mantle cell lymphoma in older adults

Muñoz,

Tsang,

Wang

et al. 2024

Leukemia & Lymphoma

View full text Add to dashboard Cite

Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis

Abstract: Not available.

Cited by 3 publications

References 14 publications

Efficacy of front‐line immunochemotherapy for transplant‐ineligible mantle cell lymphoma: A network meta‐analysis of randomized controlled trials

Efficacy of front‐line immunochemotherapy for transplant‐ineligible mantle cell lymphoma: A network meta‐analysis of randomized controlled trials

Survival Outcomes of Patients with Mantle Cell Lymphoma: A Retrospective, 15-Year, Real-Life Study

Challenges of treating mantle cell lymphoma in older adults

Contact Info

Product

Resources

About